跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber
, Danan Li
, Young Chul Song
,
Mei-Chih Liang
, Beow Y. Yeap
, Roderick T. Bronson
, Eugene Lifshits
, Zhao Chen
, Sauveur Michel Maira
, Carlos García-Echeverría
, Kwok Kin Wong
*
, Jeffrey A. Engelman
*
此作品的通信作者
生物科技學系
研究成果
:
Article
›
同行評審
281
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Epidermal Growth Factor Receptor
100%
Apoptosis Induction
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
PI3K Inhibitor
100%
Differential Induction
100%
Apoptosis
71%
Mammalian Target of Rapamycin (mTOR)
71%
MEK Inhibitor (MEKi)
57%
Lung Cancer
42%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
42%
Myeloid Cell leukemia-1 (Mcl-1)
42%
Induced Apoptosis
28%
MTOR Inhibitor
28%
PI3K-mTOR Inhibitors
28%
Tumor
14%
Small Interfering RNA (siRNA)
14%
Acquired Resistance
14%
Tyrosine Kinase Inhibitor
14%
Xenograft Model
14%
Dual Inhibition
14%
Effective Strategies
14%
T790M
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Gefitinib
14%
NVP-BEZ235
14%
Erlotinib
14%
L858R
14%
HER2-amplified Breast Cancer
14%
Transgenic Mouse Model
14%
Activating mutation
14%
ERK Pathway
14%
MEK Signaling
14%
AKT Inhibitor
14%
Epidermal Growth Factor Receptor Inhibitors
14%
Intracellular Signaling
14%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Programmed Cell Death
100%
Mammalian Target of Rapamycin
63%
Downregulation
45%
Receptor Tyrosine Kinase Inhibitors
27%
MEK Inhibitor
27%
Upregulation
9%
Tyrosine Kinase Inhibitor
9%
Transgenics
9%
Small Interfering RNA
9%
Erlotinib
9%
Gefitinib
9%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Lung Cancer
37%
Epidermal Growth Factor Receptor Kinase Inhibitor
37%
Mitogen Activated Protein Kinase Kinase Inhibitor
37%
Mammalian Target of Rapamycin Inhibitor
25%
Breast Cancer
12%
Neoplasm
12%
Non Small Cell Lung Cancer
12%
Protein Tyrosine Kinase Inhibitor
12%
Small Interfering RNA
12%
Gefitinib
12%
Dactolisib
12%
Erlotinib
12%